Clemens O Hanemann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3329807/publications.pdf

Version: 2024-02-01

144 papers	7,033 citations	53794 45 h-index	71685 76 g-index
155 all docs	155 docs citations	155 times ranked	7260 citing authors

#	Article	IF	Citations
1	Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma. Cancer Research, 2022, 82, 235-247.	0.9	11
2	Clinical trials in pediatric ALS: a TRICALS feasibility study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 481-488.	1.7	3
3	The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. Journal of the Neurological Sciences, 2022, 436, 120188.	0.6	3
4	Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genetics in Medicine, 2022, 24, 1967-1977.	2.4	60
5	Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas. International Journal of Molecular Sciences, 2021, 22, 560.	4.1	12
6	Biomarkers for differentiating grade II meningiomas from grade I: a systematic review. British Journal of Neurosurgery, 2021, 35, 696-702.	0.8	7
7	Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use. Neurology, 2021, 97, S91-S98.	1.1	19
8	Do pain, anxiety and depression influence quality of life for people with amyotrophic lateral sclerosis/motor neuron disease? A national study reconciling previous conflicting literature. Journal of Neurology, 2020, 267, 607-615.	3.6	25
9	Constitutive activation of the EGFRâ€“STAT1 axis increases proliferation of meningioma tumor cells. Neuro-Oncology Advances, 2020, 2, vdaa008.	0.7	9
10	A Systematic Approach to Review of in vitro Methods in Brain Tumour Research (SAToRI-BTR): Development of a Preliminary Checklist for Evaluating Quality and Human Relevance. Frontiers in Bioengineering and Biotechnology, 2020, 8, 936.	4.1	1
11	GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma. EBioMedicine, 2020, 59, 102941.	6.1	17
12	Integration and Comparison of Transcriptomic and Proteomic Data for Meningioma. Cancers, 2020, 12, 3270.	3.7	8
13	Measuring quality of life in ALS/MND: validation of the WHOQOL-BREF. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 364-372.	1.7	5
14	The Potential of MLN3651 in Combination with Selumetinib as a Treatment for Merlin-Deficient Meningioma. Cancers, 2020, 12, 1744.	3.7	0
15	A Rapid Robust Method for Subgrouping Non-NF2 Meningiomas According to Genotype and Detection of Lower Levels of M2 Macrophages in AKT1 E17K Mutated Tumours. International Journal of Molecular Sciences, 2020, 21, 1273.	4.1	10
16	HuR/ELAVL1 drives malignant peripheral nerve sheath tumor growth and metastasis. Journal of Clinical Investigation, 2020, 130, 3848-3864.	8.2	38
17	Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine, 2019, 40, 77-91.	6.1	54
18	Advances in multidisciplinary therapy for meningiomas. Neuro-Oncology, 2019, 21, i18-i31.	1.2	102

#	Article	IF	Citations
19	The relationships between symptoms, disability, perceived health and quality of life in amyotrophic lateral sclerosis/motor neuron disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 317-327.	1.7	27
20	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro-Oncology, 2019, 21, 901-910.	1.2	184
21	Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity. Clinical Genetics, 2019, 96, 151-162.	2.0	18
22	Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology. British Journal of Radiology, 2019, 92, 20190059.	2.2	4
23	Phase 0 trial investigating the intratumoural concentration and activity of sorafenib in neurofibromatosis type 2. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1184-1187.	1.9	4
24	CSIG-02. TARGETING CONSTITUTIVE ACTIVATION OF THE EGFR-STAT1 AXIS DECREASES PROLIFERATION OF MENINGIOMA TUMOUR CELLS. Neuro-Oncology, 2019, 21, vi44-vi44.	1.2	0
25	Progression of hearing loss in neurofibromatosis type 2 according to genetic severity. Laryngoscope, 2019, 129, 974-980.	2.0	21
26	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. Neuro-Oncology, 2019, 21, i32-i43.	1.2	56
27	Imaging and diagnostic advances for intracranial meningiomas. Neuro-Oncology, 2019, 21, i44-i61.	1.2	100
28	Molecular and translational advances in meningiomas. Neuro-Oncology, 2019, 21, i4-i17.	1.2	92
29	Development and validation of Spasticity Index-Amyotrophic Lateral Sclerosis. Acta Neurologica Scandinavica, 2018, 138, 47-54.	2.1	7
30	An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures. Scientific Reports, 2018, 8, 13537.	3.3	49
31	Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. EBioMedicine, 2017, 16, 76-86.	6.1	22
32	Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Lossâ€“Driven Tumorigenesis. Molecular Cancer Therapeutics, 2017, 16, 1693-1704.	4.1	31
33	An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis. Cancer Research, 2017, 77, 5026-5038.	0.9	17
34	Cellular prion protein (PrPC) in the development of Merlin-deficient tumours. Oncogene, 2017, 36, 6132-6142.	5.9	24
35	Accumulation of autophagosomes confers cytotoxicity. Journal of Biological Chemistry, 2017, 292, 13599-13614.	3.4	122
36	A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 1-9.	1.7	20

#	Article	IF	Citations
37	Delta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis. Oncotarget, 2016, 7, 46603-46614.	1.8	41
38	Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology, 2016, 36, 250-261.	1.2	28
39	Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology, 2016, 87, S40-8.	1.1	23
40	The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors. Oncogene, 2016, 35, 3443-3453.	5.9	13
41	DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis â€“ a randomised controlled trial. Health Technology Assessment, 2016, 20, 1-186.	2.8	13
42	The p53/mouse double minute 2 homolog complex deregulation in merlinâ€deficient tumours. Molecular Oncology, 2015, 9, 236-248.	4.6	17
43	Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurology, The, 2015, 14, 883-892.	10.2	85
44	Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. Journal of Medical Genetics, 2015, 52, 699-705.	3.2	78
45	Abstract 704: Scaffold protein KSR1 is negatively regulated by merlin and promotes tumor development in merlin deficient tumors. , 2015, , .		0
46	Schwannomas and Their Pathogenesis. Brain Pathology, 2014, 24, 205-220.	4.1	151
47	CLINICAL MORVAN'S AND ELECTRICAL MND. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.96-e4.	1.9	0
48	Artesunate induces necrotic cell death in schwannoma cells. Cell Death and Disease, 2014, 5, e1466-e1466.	6.3	49
49	Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus. Cancer Cell, 2014, 26, 48-60.	16.8	198
50	Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. Journal of Neurology, 2014, 261, 963-969.	3.6	39
51	Axl/Gas6/NFÎºB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene, 2014, 33, 336-346.	5.9	71
52	Abstract 2609: The role of focal adhesion kinase (FAK), PI3K/AKT and p53/mouse double minute 2 homologue (MDM2) complex in the pathobiology of Merlin-deficient tumors. , 2014, , .		0
53	Merlin isoform 2 in neurofibromatosis type 2â€“associated polyneuropathy. Nature Neuroscience, 2013, 16, 426-433.	14.8	51
54	Management of sialorrhoea in motor neuron disease: A survey of current UK practice. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 521-527.	1.7	28

#	Article	IF	Citations
55	Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2013, 12, 339-345.	10.2	118
56	Conclusions and future directions for the REiNS International Collaboration. Neurology, 2013, 81, S41-4.	1.1	23
57	Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells. Brain, 2013, 136, 549-563.	7.6	35
58	Achieving consensus for clinical trials. Neurology, 2013, 81, S1-5.	1.1	59
59	Expression of câ€‹<scp>J</scp>un and <scp>S</scp>oxâ€2 in human schwannomas and traumatic neuromas. Histopathology, 2013, 62, 651-656.	2.9	13
60	Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation. American Journal of Medical Genetics, Part A, 2013, 161, 2027-2029.	1.2	15
61	Î”9â€“TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARÎ³ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.58-e2.	1.9	1
62	Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. Oncogene, 2012, 31, 1710-1722.	5.9	42
63	Î”⁹â€tetrahydrocannabinol (Î”⁹â€THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathology and Applied Neurobiology, 2012, 38, 535-547.	3.2	84
64	The Tumor Suppressor Merlin Controls Growth in Its Open State, and Phosphorylation Converts It to a Less-Active More-Closed State. Developmental Cell, 2012, 22, 703-705.	7.0	56
65	The role of insulinâ€like growth factors signaling in merlinâ€deficient human schwannomas. Glia, 2012, 60, 1721-1733.	4.9	21
66	Merlin, a multiâ€suppressor from cell membrane to the nucleus. FEBS Letters, 2012, 586, 1403-1408.	2.8	54
67	Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. American Journal of Medical Genetics, Part A, 2012, 158A, 24-41.	1.2	101
68	Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/Î²-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways. Neoplasia, 2011, 13, 1101-IN2.	5.3	83
69	Changes in iron-regulatory gene expression occur in human cell culture models of Parkinsonâ€™s disease. Neurochemistry International, 2011, 59, 73-80.	3.8	26
70	Cannabinoid Receptor and Nâ€acyl Phosphatidylethanolamine Phospholipase Dâ€”Evidence for Altered Expression in Multiple Sclerosis. Brain Pathology, 2011, 21, 544-557.	4.1	37
71	Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro-Oncology, 2011, 13, 759-766.	1.2	46
72	Emerging therapeutic targets in schwannomas and other merlin-deficient tumors. Nature Reviews Neurology, 2011, 7, 392-399.	10.1	71

#	Article	IF	Citations
73	Merlin/NF2 Functions Upstream of the Nuclear E3 Ubiquitin Ligase CRL4 ^{DCAF1} to Suppress Oncogenic Gene ExpressionA presentation from the 50th Annual Meeting of the American Society for Cell Biology in Philadelphia, Pennsylvania, 11 to 15 December 2010.. Science Signaling, 2011, 4, pt6.	3.6	45
74	The epidemiology of motor neurone disease in two counties in the southwest of England. Journal of Neurology, 2010, 257, 977-981.	3.6	11
75	Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon. Journal of Neurology, 2010, 257, 2094-2096.	3.6	3
76	Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244. Neurobiology of Disease, 2010, 37, 141-146.	4.4	24
77	Acquired rippling muscle disease in association with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 125-126.	1.9	7
78	ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro-Oncology, 2010, 12, 834-843.	1.2	81
79	Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus. Cell, 2010, 140, 477-490.	28.9	287
80	Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology, 2009, 55, 744-749.	2.9	37
81	Altered Adhesive Structures and Their Relation to RhoGTPase Activation in Merlinâ€Deficient Schwannoma. Brain Pathology, 2009, 19, 27-38.	4.1	27
82	PAK kinase regulates Rac GTPase and is a potential target in human schwannomas. Experimental Neurology, 2009, 218, 137-144.	4.1	34
83	Acquired neuromyotonia following upper respiratory tract infection: a case report. Cases Journal, 2009, 2, 7952.	0.4	6
84	Abstract C164: Targeting receptor tyrosine kinases and their downstream signaling pathways in human schwannoma. , 2009, , .		0
85	High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells. Journal of Neuroscience Research, 2008, 86, 3212-3220.	2.9	25
86	Impaired intercellular adhesion and immature adherens junctions in merlinâ€deficient human primary schwannoma cells. Glia, 2008, 56, 506-515.	4.9	30
87	Magic but treatable? Tumours due to loss of Merlin. Brain, 2008, 131, 606-615.	7.6	80
88	Dissecting and Targeting the Growth Factorâ€“Dependent and Growth Factorâ€“Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma. Cancer Research, 2008, 68, 5236-5245.	0.9	115
89	Neurofibromatosis type 1 with involvement of the enteric nerves. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1163-1164.	1.9	13
90	Actin-Rich Protrusions and Nonlocalized GTPase Activation in Merlin-Deficient Schwannomas. Journal of Neuropathology and Experimental Neurology, 2007, 66, 608-616.	1.7	29

#	Article	IF	Citations
91	Role of NF2 Haploinsufficiency in NF2â€associated Polyneuropathy. Brain Pathology, 2007, 17, 371-376.	4.1	19
92	Differential gene expression between human schwannoma and control Schwann cells. Neuropathology and Applied Neurobiology, 2006, 32, 605-614.	3.2	36
93	A functional association between merlin and HEI10, a cell cycle regulator. Oncogene, 2006, 25, 4389-4398.	5.9	27
94	News on the genetics, epidemiology, medical care and translational research of Schwannomas. Journal of Neurology, 2006, 253, 1533-1541.	3.6	49
95	Heterozygous R1101K mutation of theDCTN1 gene in a family with ALS and FTD. Annals of Neurology, 2005, 58, 777-780.	5.3	182
96	Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology, 2005, 64, 753-754.	1.1	45
97	Motor protein diseases of the nervous system. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 197-201.	2.1	4
98	MR-Pathologic Comparison of the Upper Spinal Cord in Different Motor Neuron Diseases. European Neurology, 2005, 53, 74-77.	1.4	27
99	Fludeoxyglucose F 18 Positron Emission Tomography and Computed Tomography of a Giant Retroperitoneal Schwannoma Occurring in a Patient With Neurofibromatosis Type 2. Archives of Neurology, 2005, 62, 674.	4.5	13
100	Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228. Cancer Biology and Therapy, 2005, 4, 385-387.	3.4	31
101	Sensitive Detection of Deletions of One or More Exons in the Neurofibromatosis Type 2 (NF2) Gene by Multiplexed Gene Dosage Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2005, 7, 97-104.	2.8	13
102	Rearrangements of the intermediate filament GFAP in primary human schwannoma cells. Neurobiology of Disease, 2005, 19, 1-9.	4.4	16
103	Reduced Apoptosis Rates in Human Schwannomas. Brain Pathology, 2005, 15, 17-22.	4.1	28
104	Kennedy Disease: Insights and Questionsâ€”Reply. Archives of Neurology, 2004, 61, 603.	4.5	1
105	FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. Journal of Medical Genetics, 2004, 41, e50-e50.	3.2	82
106	Complicated hereditary spastic paraplegia with thin corpus callosum: Variation of phenotypic expression over time. Journal of Neurology, 2004, 251, 1285-1287.	3.6	13
107	A Clue to the Therapy of Neurofibromatosis Type 2. Cancer Journal (Sudbury, Mass), 2004, 10, 20-25.	2.0	91
108	Quinidine impairs proliferation of neurofibromatosis type 2â€deficient human malignant mesothelioma cells. Cancer, 2003, 97, 1955-1962.	4.1	18

#	Article	IF	Citations
109	Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Therapy, 2003, 10, 84-94.	4.5	91
110	Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Human Molecular Genetics, 2003, 12, 1211-1221.	2.9	107
111	Transient, Recurrent, White Matter Lesions in X-linked Charcot-Marie-Tooth Disease With Novel Connexin 32 Mutation. Archives of Neurology, 2003, 60, 605.	4.5	111
112	A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease. Brain, 2003, 126, 920-927.	7.6	26
113	Pathological Adhesion of Primary Human Schwannoma Cells is Dependent on Altered Expression of Integrins. Brain Pathology, 2003, 13, 352-363.	4.1	32
114	Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Human Molecular Genetics, 2002, 11, 69-76.	2.9	66
115	Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain, 2002, 125, 996-1004.	7.6	122
116	Hereditary motor neuropathies and motor neuron diseases: which is which. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2002, 3, 186-189.	1.2	12
117	X-linked Bulbospinal Neuronopathy. Archives of Neurology, 2002, 59, 1921.	4.5	206
118	Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies. Current Opinion in Neurology, 2002, 15, 611-615.	3.6	21
119	Erratum to â€œAxon damage in CMT due to mutation in myelin protein P0â€•[Neuromusc. Disord. 11 (2001) 753â€“756]. Neuromuscular Disorders, 2002, 12, 432.	0.6	1
120	Spinal Neurofibromatosis without CafÃ©-au-Lait Macules in Two Families with Null Mutations of the NF1 Gene. American Journal of Human Genetics, 2001, 69, 1395-1400.	6.2	41
121	Enhanced Proliferation and Potassium Conductance of Schwann Cells Isolated from NF2 Schwannomas Can Be Reduced by Quinidine. Neurobiology of Disease, 2001, 8, 181.	4.4	0
122	Axon damage in CMT due to mutation in myelin protein P0. Neuromuscular Disorders, 2001, 11, 753-756.	0.6	32
123	Hereditary demyelinating neuropathies: from gene to disease. Neurogenetics, 2001, 3, 53-57.	1.4	8
124	Long-term culture and characterization of human neurofibroma-derived Schwann cells. Journal of Neuroscience Research, 2000, 61, 524-532.	2.9	46
125	Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcotâ€“Marieâ€“Tooth type 1A. Brain, 2000, 123, 1001-1006.	7.6	46
126	Enhanced Proliferation and Potassium Conductance of Schwann Cells Isolated from NF2 Schwannomas Can Be Reduced by Quinidine. Neurobiology of Disease, 2000, 7, 483-491.	4.4	16

#	Article	IF	Citations
127	Longâ€term culture and characterization of human neurofibromaâ€derived Schwann cells. Journal of Neuroscience Research, 2000, 61, 524-532.	2.9	0
128	Cellular contaminants of adeno-associated virus vector stocks can enhance transduction. Gene Therapy, 1999, 6, 1045-1053.	4.5	26
129	Muscle injury in Guillain-BarrÃ© syndrome: a case report. Journal of Neurology, 1999, 246, 1207-1208.	3.6	2
130	Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type 1 and hereditary neuropathy with liability to pressure palsies. , 1998, 21, 1419-1427.		15
131	Improved culture methods to expand schwann cells with altered growth behaviour from CMT1A patients. , 1998, 23, 89-98.		48
132	Voltage-dependent membrane currents of cultured human neurofibromatosis type 2 Schwann cells. , 1998, 24, 313-322.		19
133	Pathogenesis of Charcotâ€“Marieâ€“Tooth 1A (CMT1A) neuropathy. Trends in Neurosciences, 1998, 21, 282-286.	8.6	63
134	Isolation and Characterization of Schwann Cells from Neurofibromatosis Type 2 Patients. Neurobiology of Disease, 1998, 5, 55-64.	4.4	62
135	Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs. Acta Neuropathologica, 1997, 94, 310-315.	7.7	51
136	Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region. Annals of Neurology, 1997, 42, 364-368.	5.3	87
137	Lack of immune responses to immediate or delayed implanted allogeneic and xenogeneic Schwann cell suspensions. Glia, 1997, 21, 299-314.	4.9	14
138	Low affinity NGF receptor expression in CMT1 A nerve biopsies of different disease stages. Brain, 1996, 119, 1461-1469.	7.6	43
139	PMP22 expression in CMT1A neuropathy. Annals of Neurology, 1995, 37, 136-136.	5.3	6
140	Peripheral myelin protein-22 expression in charcot-marie-tooth disease type 1a sural nerve biopsies. Journal of Neuroscience Research, 1994, 37, 654-659.	2.9	72
141	Balo's concentric sclerosis followed by MRI and positron emission tomography. Neuroradiology, 1993, 35, 578-580.	2.2	29
142	Expression of decorin mRNA in the nervous system of rat.. Journal of Histochemistry and Cytochemistry, 1993, 41, 1383-1391.	2.5	31
143	The peripheral myelin protein gene PMPâ€“22 is contained within the Charcotâ€“Marieâ€“Tooth disease type 1A duplication. Nature Genetics, 1992, 1, 171-175.	21.4	404
144	Peripheral myelin proteinâ€“22 gene maps in the duplication in chromosome 17p11.2 associated with Charcotâ€“Marieâ€“Tooth 1A. Nature Genetics, 1992, 1, 176-179.	21.4	325